Key Points
- Insider sale: Pharvaris insider Peng Lu sold 300 shares on June 18 at an average price of $34.00, totaling $10,200. After the sale, Lu still held 65,631 shares, and the transaction reduced ownership by just 0.46%.
- Recent trading activity: This follows several larger sales by Lu in late April, including transactions of 3,733 shares, 15,000 shares, 100 shares, and 7,001 shares at around $30 per share.
- Stock and analyst outlook: Pharvaris shares were up 0.6% to $33.19, near the 12-month high of $34.41. Analysts remain generally positive, with a consensus Moderate Buy rating and an average price target of $49.18.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Peng Lu sold 300 shares of the company's stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $34.00, for a total transaction of $10,200.00. Following the completion of the sale, the insider directly owned 65,631 shares of the company's stock, valued at $2,231,454. The trade was a 0.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Peng Lu also recently made the following trade(s):
- On Wednesday, April 29th, Peng Lu sold 3,733 shares of Pharvaris stock. The shares were sold at an average price of $30.06, for a total transaction of $112,213.98.
- On Thursday, April 30th, Peng Lu sold 15,000 shares of Pharvaris stock. The stock was sold at an average price of $30.24, for a total transaction of $453,600.00.
- On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.
- On Wednesday, April 22nd, Peng Lu sold 7,001 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,380.05.
Pharvaris Trading Up 0.6%
Shares of Pharvaris stock opened at $33.19 on Wednesday. The business's fifty day simple moving average is $30.27 and its 200 day simple moving average is $27.84. The firm has a market capitalization of $2.17 billion, a P/E ratio of -10.44 and a beta of -2.35. Pharvaris N.V. has a 12 month low of $16.72 and a 12 month high of $34.41.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.82) by $0.12. Analysts predict that Pharvaris N.V. will post -3.22 EPS for the current fiscal year.
Institutional Trading of Pharvaris
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Tudor Investment Corp ET AL bought a new position in shares of Pharvaris in the third quarter worth $1,943,000. Patient Square Capital LP raised its position in shares of Pharvaris by 41.4% in the third quarter. Patient Square Capital LP now owns 345,381 shares of the company's stock worth $8,617,000 after buying an additional 101,098 shares in the last quarter. Integral Health Asset Management LLC bought a new stake in Pharvaris during the third quarter valued at $4,990,000. JPMorgan Chase & Co. boosted its stake in Pharvaris by 710.4% during the third quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company's stock valued at $676,000 after buying an additional 23,743 shares during the period. Finally, PSP Research LLC purchased a new position in Pharvaris during the fourth quarter worth about $569,000.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on PHVS. Wolfe Research initiated coverage on shares of Pharvaris in a research report on Thursday, April 9th. They set an "outperform" rating and a $42.00 price target for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a research report on Tuesday, April 21st. Wedbush boosted their target price on shares of Pharvaris from $41.00 to $42.00 and gave the company an "outperform" rating in a research note on Tuesday, April 7th. Royal Bank Of Canada reduced their target price on shares of Pharvaris from $52.00 to $51.00 and set an "outperform" rating for the company in a research report on Monday, April 6th. Finally, Citizens Jmp lowered their price target on shares of Pharvaris from $75.00 to $74.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 13th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $49.18.
Check Out Our Latest Stock Analysis on PHVS
About Pharvaris
(
Get Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
